Aclarion Inc. (NASDAQ:ACON) saw its stock rise 6.3% in premarket trading Thursday after announcing that its Nociscan technology will be featured in the Special Pain Issue of the International Journal of Spine Surgery (IJSS).
The health tech company, which leverages biomarkers and AI-driven analysis to help clinicians pinpoint the source of chronic low back pain, was profiled in a Tech Update article sponsored by Aclarion for the upcoming issue.
The publication spotlighted a case involving a 27-year-old patient suffering from chronic low back pain. In that example, Nociscan enabled the operating surgeon to determine that only one spinal disc required intervention—contrary to MRI results that initially suggested two problematic levels. This more targeted treatment plan ultimately led to full pain relief and a return to active daily living for the patient.
“We are pleased that the Nociscan Tech Update is featured in the Special Pain Issue of such a high caliber journal like IJSS,” said Ryan Bond, Chief Strategy Officer at Aclarion. “The journal has long been a leader among its peers for advancing scientific and clinical excellence in spine care.”
Nociscan is described as the first evidence-backed SaaS platform capable of noninvasively differentiating between painful and non-painful discs in the lumbar spine. Aclarion aims to address the global population of roughly 266 million people affected by chronic low back pain.
The International Journal of Spine Surgery is a peer-reviewed publication dedicated to educating spine surgeons on the science, indications, surgical methods, and clinical outcomes associated with spinal procedures.